Background and Objectives: Inconsistencies in nasal nitric oxide (nNO) values, due to anatomical variations and comorbidities, challenge the accurate assessment of upper airway inflammation severity. We hypothesized that changes in nNO levels following treatment for chronic rhinitis would be consistent and provide relative value. This study aimed to evaluate the correlation between changes in nNO levels and symptomatic improvements following treatment for chronic rhinitis. Methods: This prospective observational study included 46 participants diagnosed with chronic rhinitis between December 2021 and November 2023. nNO measurements, evaluations of four nasal and two ocular symptoms, and quality of life questionnaires were conducted at baseline and after one month of treatment. Baseline laboratory tests included serum total immunoglobulin E levels, blood eosinophil percentages, and skin prick tests. Results: The Total Nasal Symptom Score (TNSS), TNSS with ocular symptoms (TNSS eye), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores significantly decreased following treatment (all p<0.001). nNO levels also decreased significantly after treatment (p=0.036). Moreover, changes in nNO were significantly correlated with changes in TNSS, TNSS eye, and RQLQ scores (p=0.047, r=0.294; p=0.021, r=0.340; and p=0.004, r=0.419, respectively). Conclusion In patients with chronic rhinitis, changes in TNSS, TNSS eye, and RQLQ scores were correlated with changes in nNO levels after treatment. nNO may serve as a potential objective evaluation tool for chronic rhinitis, particularly in patients who have difficulty reporting symptoms.

We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

Background and Objectives: Inconsistencies in nasal nitric oxide (nNO) values, due to anatomical variations and comorbidities, challenge the accurate assessment of upper airway inflammation severity. We hypothesized that changes in nNO levels following treatment for chronic rhinitis would be consistent and provide relative value. This study aimed to evaluate the correlation between changes in nNO levels and symptomatic improvements following treatment for chronic rhinitis. Methods: This prospective observational study included 46 participants diagnosed with chronic rhinitis between December 2021 and November 2023. nNO measurements, evaluations of four nasal and two ocular symptoms, and quality of life questionnaires were conducted at baseline and after one month of treatment. Baseline laboratory tests included serum total immunoglobulin E levels, blood eosinophil percentages, and skin prick tests. Results: The Total Nasal Symptom Score (TNSS), TNSS with ocular symptoms (TNSS eye), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores significantly decreased following treatment (all p<0.001). nNO levels also decreased significantly after treatment (p=0.036). Moreover, changes in nNO were significantly correlated with changes in TNSS, TNSS eye, and RQLQ scores (p=0.047, r=0.294; p=0.021, r=0.340; and p=0.004, r=0.419, respectively). Conclusion In patients with chronic rhinitis, changes in TNSS, TNSS eye, and RQLQ scores were correlated with changes in nNO levels after treatment. nNO may serve as a potential objective evaluation tool for chronic rhinitis, particularly in patients who have difficulty reporting symptoms.

We describe the updated Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of cervical cancer, version 5.1. The KSGO announced the fifth version of its clinical practice guidelines for the management of cervical cancer in March 2024. The selection of the key questions and the systematic reviews were based on data available up to December 2022. Between 2023 and 2024, substantial findings from large-scale clinical trials and new advancements in cervical cancer research remarkably emerged. Therefore, based on the existing version 5.0, we updated the guidelines with newly accumulated clinical data and added 4 new key questions reflecting the latest insights in the field of cervical cancer. For each question, recommendation was formulated with corresponding level of evidence and grade of recommendation, all established through expert consensus.

Background and Objectives: Inconsistencies in nasal nitric oxide (nNO) values, due to anatomical variations and comorbidities, challenge the accurate assessment of upper airway inflammation severity. We hypothesized that changes in nNO levels following treatment for chronic rhinitis would be consistent and provide relative value. This study aimed to evaluate the correlation between changes in nNO levels and symptomatic improvements following treatment for chronic rhinitis. Methods: This prospective observational study included 46 participants diagnosed with chronic rhinitis between December 2021 and November 2023. nNO measurements, evaluations of four nasal and two ocular symptoms, and quality of life questionnaires were conducted at baseline and after one month of treatment. Baseline laboratory tests included serum total immunoglobulin E levels, blood eosinophil percentages, and skin prick tests. Results: The Total Nasal Symptom Score (TNSS), TNSS with ocular symptoms (TNSS eye), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores significantly decreased following treatment (all p<0.001). nNO levels also decreased significantly after treatment (p=0.036). Moreover, changes in nNO were significantly correlated with changes in TNSS, TNSS eye, and RQLQ scores (p=0.047, r=0.294; p=0.021, r=0.340; and p=0.004, r=0.419, respectively). Conclusion In patients with chronic rhinitis, changes in TNSS, TNSS eye, and RQLQ scores were correlated with changes in nNO levels after treatment. nNO may serve as a potential objective evaluation tool for chronic rhinitis, particularly in patients who have difficulty reporting symptoms.

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

Background: Employees with depression have complex and serious health consequences, not only for them, including reduced quality of life, but also for businesses and society, leading to social costs such as reduced productivity. This study investigated the prevalence of depressive symptoms and related factors among public enterprise employees in Naju Innovation City, Korea. Methods: We investigated the sociodemographic and psychosocial characteristics of 1,061 public enterprise employees. Depression, anxiety, and occupational burnout were assessed using the Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Maslach Burnout Inventory-General Survey, respectively. Furthermore, the impact of factors on depressive symptoms was examined using a logistic regression model. Results: The prevalence of overall depressive symptoms was 11.9%. High anxiety (odds ratio [OR]=12.19; 95% confidence interval [CI]=7.17-20.76; p<0.001) and exhaustion (OR=2.79; 95% CI=1.81-4.40; p<0.001) levels were significantly associated with depressive symptoms. Conclusion Anxiety symptoms and exhaustion were the most important factors related to depressive symptoms among the public enterprise employees. Hence, when providing an employee assistance program, the psychosocial vulnerability factors of workers with depressive symptoms should be thoroughly addressed.2

This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as firstor second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.